Refine by
Therapeutics Enter Oncology Services
6 services found
by:Champions Oncology, Inc. based inHackensack, NEW JERSEY (USA)
Champions' Discovery Services leverages the Lumin Analytic Engine and rapid validation workflows to identify novel therapeutic targets and/or biomarkers of ...
Manufactured by:MuseChem based inPaoli, PENNSYLVANIA (USA)
Antibody-drug conjugates (ADCs) are a new class of highly potent oncology therapeutics for the treatment of people with cancer. An ADC could be divided into three main structural units: the antibody; the cytotoxic agent (drug); and the linker. The antibody has high affinity for a tumor-associated antigen that has restricted or no expression on normal cells. By combining this unique targeting ...
by:Revvity Gene Delivery (formerly SIRION Biotech) based inHamburg, GERMANY
In the discovery of oncology therapeutics, Antibody-drug conjugates (ADCs) are rapidly gaining momentum, with hundreds of candidates advancing through clinical development. Whether your priority lies in assessing the epitope binding of your construct, evaluating the cytotoxic potency of the payload, or scrutinizing the efficacy of the linker in cleaving, each facet demands meticulous ...
by:Champions Oncology, Inc. based inHackensack, NEW JERSEY (USA)
Champions Oncology's ex vivo AML co-culture platform for Immuno-Oncology therapeutic testing. Champions Oncology has launched an innovative new platform enabling Acute Myeloid Leukemia (AML) researchers the ability to better understand their therapeutic mechanism of action. The Autologous AML Platform is an ex vivo co-culture assay developed and optimized to interrogate the responses of your ...
by:Champions Oncology, Inc. based inHackensack, NEW JERSEY (USA)
Champions Oncology's ex vivo 3D co-culture platform for Immuno-Oncology therapeutic testing. Champions Oncology has launched an innovative new platform enabling Immuno-Oncology researchers the ability to test their therapeutics in a 3D organoid assay that can mimic mechanism of action. The Autologous TIL platform is an ex vivo 3D co-culture platform developed and optimized to interrogate the ...
Manufactured by:XILIS, Inc. based inDurham, NORTH CAROLINA (USA)
Xilis’ rapid and scalable patient-derived MicroOrganoSphere (MOS) technology platform enhances precision medicine and pharmaceutical drug discovery and development. Compared to conventional patient-derived models, MOS provides faster, higher-throughput, and greater cost savings, as well as more predictive and accurate results. MOS can be used in large-scale pharmacogenomic studies that are ...